{"slideshow_credits": null, "snippet": "As Valeant Pharmaceuticals\u2019 market value sinks, the company\u2019s future may hinge on what it can get now for the companies it bought.", "abstract": "Gretchen Morgenson Fair Game column addresses question of how to determine worth of Valeant Pharmaceuticals, in light of steep drop in company's shares; notes analysts have doubts about company's ability to raise cash, despite Pershing Square Capital Management William A Ackman's assurances.", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Gretchen", "role": "reported", "lastname": "MORGENSON", "rank": 1, "organization": ""}], "original": "By GRETCHEN MORGENSON"}, "web_url": "http://www.nytimes.com/2016/03/16/business/figuring-out-what-valeant-is-really-worth.html", "lead_paragraph": "As Valeant Pharmaceuticals\u2019 market value sinks, the company\u2019s future may hinge on what it can get now for the companies it bought.", "headline": {"print_headline": "Figuring Valeant\u2019s True Value", "main": "Figuring Out What Valeant Is Really Worth", "content_kicker": "Fair Game", "kicker": "Fair Game"}, "_id": "56e892eb38f0d85c820e6404", "word_count": "859", "multimedia": [], "pub_date": "2016-03-16T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "organizations", "value": "Valeant Pharmaceuticals International Inc", "is_major": "Y", "rank": "1"}, {"name": "organizations", "value": "Pershing Square Capital Management", "is_major": "Y", "rank": "2"}, {"name": "persons", "value": "Ackman, William A", "is_major": "Y", "rank": "3"}, {"name": "subject", "value": "Company Reports", "is_major": "N", "rank": "4"}], "blog": [], "subsection_name": null, "type_of_material": "An Analysis; News Analysis"}